뒤로
Alphamab Oncology(09966.HK) 가격
09966.HK 주가 차트
ALPHAMAB-B (09966.HK)
Alphamab Oncology
HK$0
0%
$0
정규장: Jan 20, 11:22:54 HKT
아직 데이터 없음Earnings FAQ
09966.HK의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Alphamab Oncology 09966.HK의 지난 분기 매출 실적은 어땠나요?
Alphamab Oncology의 매출 추정치는 얼마인가요?
Alphamab Oncology의 수익 품질 점수는 얼마인가요?
Alphamab Oncology는 언제 수익을 보고하나요?
Alphamab Oncology의 예상 수익은 얼마인가요?
Alphamab Oncology은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$9.82
시가
--
일일 범위
-
52주 범위
-
거래량
--
평균 거래량
2.5M
EPS(TTM)
0.27
배당수익률
--
시가총액
--
ALPHAMAB-B란 무엇인가요?
Alphamab Oncology is an investment holding company. The company is headquartered in Suzhou, Jiangsu and currently employs 484 full-time employees. The company went IPO on 2019-12-12. The Company’s in-house pipeline consists of antibody-drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s product pipeline includes KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), JSKN016(HER3/TROP2 bispecific antibody ADC), JSKN033(subcutaneous co-formulation of JSKN003 and KN035), used for indications such as 1L sq NSCLC, 1L HER2+ BC, 1L biliary track cancer, advanced solid tumors, HER2-expressing solid tumors and others.